期刊
CURRENT PSYCHIATRY REPORTS
卷 17, 期 8, 页码 -出版社
SPRINGER
DOI: 10.1007/s11920-015-0603-z
关键词
Bipolar disorder; Mood stabilizers; Adverse effects; Management
类别
资金
- Carlos III Institute, Spanish Ministry of Science and Innovation [CD13/0149]
- Adamed
- Janssen-Cilag
- Lundbeck
- Ferrer
- Jansen-Cilag
- Almirall
- AstraZeneca
- Bial
- Bristol-Myers Squibb
- Elan
- Eli Lilly
- Forest Research Institute
- Gedeon Richter
- Glaxo-Smith-Kline
- Jazz
- MSD
- Novartis
- Organon
- Otsuka
- Pfizer Inc
- PierreFabre
- Roche
- Sanofi-Aventis
- Servier
- Solvay
- Takeda
- Teva
- UBC
- Wyeth
- Spanish Ministry of Health
- Spanish Ministry of Science and Education
- Spanish Ministry of Economy and Competiveness
- Stanley Medical Research Institute
- 7th Framework Program of the European Union
Mood stabilizers such as lithium and anticonvulsants are still standard-of-care for the acute and long-term treatment of bipolar disorder (BD). This systematic review aimed to assess the prevalence of their adverse effects (AEs) and to provide recommendations on their clinical management. We performed a systematic research for studies reporting the prevalence of AEs with lithium, valproate, lamotrigine, and carbamazepine/oxcarbazepine. Management recommendations were then developed. Mood stabilizers have different tolerability profiles and are eventually associated to cognitive, dermatological, endocrine, gastrointestinal, immunological, metabolic, nephrogenic, neurologic, sexual, and teratogenic AEs. Most of those can be transient or dose-related and can be managed by optimizing drug doses to the lowest effective dose. Some rare AEs can be serious and potentially lethal, and require abrupt discontinuation of medication. Integrated medical attention is warranted for complex somatic AEs. Functional remediation and psychoeducation may help to promote awareness on BD and better medication management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据